Manufacturing and stability testing of new HIV RNA vaccines
Project-002
This project will make and prepare two experimental self-amplifying RNA HIV vaccines intended to help prevent or treat HIV for people at risk or eligible for future vaccine trials.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11307528 on NIH RePORTER |
What this research studies
From a patient perspective, the team will produce two vaccine candidates made from self-amplifying RNA that carry HIV envelope proteins, and package them in a nanostructured lipid carrier to help delivery into cells. They will follow current Good Manufacturing Practices (cGMP) to produce sterile vaccine batches, and set up an ICH-compliant stability program to monitor how the vaccines hold up over time. The work focuses on two specific HIV Env designs that can be made as secreted nanoparticles or membrane-anchored forms, depending on earlier lab findings. These steps are meant to prepare the vaccine candidates for later safety and effectiveness testing in people.
Who could benefit from this research
Good fit: Ideal future participants would be adults who are at risk for HIV or who meet eligibility for Phase 1/2 vaccine trials once the candidates are cleared for human testing.
Not a fit: People who are not at risk for HIV, those with medical reasons preventing vaccination, or those who cannot join future clinical trials are unlikely to benefit directly from this manufacturing project.
Why it matters
Potential benefit: If successful, this could lead to vaccine candidates that move into human trials and eventually help prevent HIV infection or guide therapeutic vaccine approaches.
How similar studies have performed: mRNA vaccines have shown strong success for COVID-19, but saRNA/NLC HIV vaccine approaches are newer and remain largely preclinical with limited human data so far.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Stamatatos, Leonidas — Fred Hutchinson Cancer Center
- Study coordinator: Stamatatos, Leonidas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.